REVIEW article
Front. Cell. Infect. Microbiol.
Sec. Antibiotic Resistance and New Antimicrobial drugs
This article is part of the Research TopicRevolutionizing Antimicrobial Strategies: Beyond Traditional AntibioticsView all articles
Antimicrobial peptides: Natural templates for next-generation therapeutics for antimicrobial resistance
Provisionally accepted- Institute of Bio-Resources and Sustainable Development (IBSD), Imphal, India
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Antimicrobial resistance is a growing global health crisis, responsible for nearly five million deaths annually and projected to double by 2050 as conventional antibiotics fail against multidrug-resistant pathogens. AMR is aggravated by antibiotic misuse, weak regulations, inadequate prevention, high treatment costs, and the limited discovery of new antimicrobials. In this context, antimicrobial peptides, including natural, synthetic, and computationally designed variants, have emerged as promising alternatives. AMPs display broad-spectrum antibacterial, antifungal, antiviral, antiparasitic, antibiofilm, and immunomodulatory activities, with a lower tendency to induce resistance. Their mechanisms include membrane disruption, intracellular targeting, immune modulation, and selective binding to negatively charged microbial membranes. Structural features such as α-helices, β-sheets, cyclic motifs, and post-translational modifications enhance potency and specificity. Recent advances in chemical modification, recombinant expression systems, nanotechnology, and AI-driven computational approaches have improved AMP stability, bioavailability, and therapeutic efficacy. Synthetic derivatives like innate defense regulators and conjugated AMPs further enhance immunomodulatory properties and reduce toxicity, while combination therapies increase effectiveness. Challenges remain, including degradation, short half-life, production costs, and microbial defenses such as biofilms and efflux pumps. Nevertheless, high-throughput sequencing and screening, structural biology, and structure–activity relationship studies continue to accelerate AMP development, positioning them as vital next-generation therapeutics against AMR.
Keywords: antibiotics, Antimicrobial activity, antimicrobial peptides, antimicrobial resistance, antimicrobials
Received: 07 Oct 2025; Accepted: 21 Nov 2025.
Copyright: © 2025 Ngashangva, Huidrom and Devi. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Indira Sarangthem Devi, sidevi1@yahoo.co.in
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.